Table 1.
COPD therapeutic regimens
| ICS-tolerant patients | ICS-intolerant patients |
|---|---|
| First line treatment options | |
| LABA | LABA |
| LAMA | LAMA |
| LABA + roflumilast | LABA + roflumilast |
| LAMA + roflumilast | LAMA + roflumilast |
| LAMA + LABA | LAMA + LABA |
| LAMA + LABA + roflumilast | LAMA + LABA + roflumilast |
| LABA/ICS | |
| LABA/ICS + roflumilast | |
| LAMA + LABA/ICS | |
| LAMA + LABA/ICS + roflumilast | |
| Second line treatment optionsa | |
| LAMA + LABA/ICS | LAMA + LABA |
Note:
a
If patients continue to exacerbate, despite existing treatment.
Abbreviations: COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist.